When It Has To Be There Stat
The Supply Chain is the Treatment Problem: When Logistics Fail, The Patient Dies This analysis synthesizes recent news reports of the supply chain dynamics of the FDA's rejection of ITM Isotope Technologies' ¹⁷⁷Lu-edotreotide (ITM-11). It serves as an educational summary for stakeholders who may have glanced at the news story without grasping the profound implications: In modern high-tech medicine, supply chain logistics are not a backend support function; they are the primary determinant of a drug's clinical success. The Core Challenge The FDA’s rejection of ITM-11 in August 2026 presents a stark paradox: A drug that works perfectly in a trial was denied approval because it could not be reliably manufactured and delivered. The COMPETE trial data showed that ITM-11 significantly extended progression-free survival for patients with neuroendocrine tumors (pNETs) compared to existing therapies. The drug’s chemistry, safety, and efficacy were never in question. However, the FDA...